Gene Therapy Market Size, Share & Growth Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Gene Therapy Market Size Analysis

Global Gene Therapy Market Introduction
By Vector
1. Introduction
  1. Vector By Value
2. Viral
  1. By Value
  2. AAV
    1. AAV By Value
  3. Lentiviral vectors
    1. Lentiviral vectors By Value
  4. Others
    1. Others By Value
3. Non-Viral
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Cancer
  1. By Value
3. Cystic fibrosis
  1. By Value
4. Heart diseases
  1. By Value
5. Diabetes
  1. By Value
6. Hemophiles
  1. By Value
7. AIDS
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Inhalation
  1. By Value

North America Market Analysis

Introduction
By Vector
1. Introduction
  1. Vector By Value
2. Viral
  1. By Value
  2. AAV
    1. AAV By Value
  3. Lentiviral vectors
    1. Lentiviral vectors By Value
  4. Others
    1. Others By Value
3. Non-Viral
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Cancer
  1. By Value
3. Cystic fibrosis
  1. By Value
4. Heart diseases
  1. By Value
5. Diabetes
  1. By Value
6. Hemophiles
  1. By Value
7. AIDS
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Inhalation
  1. By Value
U.S.
1. By Vector
  1. Introduction
    1. Vector By Value
  2. Viral
    1. By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-Viral
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Cancer
    1. By Value
  3. Cystic fibrosis
    1. By Value
  4. Heart diseases
    1. By Value
  5. Diabetes
    1. By Value
  6. Hemophiles
    1. By Value
  7. AIDS
    1. By Value
  8. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Inhalation
    1. By Value
Canada

Europe Market Analysis

Introduction
By Vector
1. Introduction
  1. Vector By Value
2. Viral
  1. By Value
  2. AAV
    1. AAV By Value
  3. Lentiviral vectors
    1. Lentiviral vectors By Value
  4. Others
    1. Others By Value
3. Non-Viral
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Cancer
  1. By Value
3. Cystic fibrosis
  1. By Value
4. Heart diseases
  1. By Value
5. Diabetes
  1. By Value
6. Hemophiles
  1. By Value
7. AIDS
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Inhalation
  1. By Value
U.K.
1. By Vector
  1. Introduction
    1. Vector By Value
  2. Viral
    1. By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-Viral
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Cancer
    1. By Value
  3. Cystic fibrosis
    1. By Value
  4. Heart diseases
    1. By Value
  5. Diabetes
    1. By Value
  6. Hemophiles
    1. By Value
  7. AIDS
    1. By Value
  8. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Inhalation
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Vector
1. Introduction
  1. Vector By Value
2. Viral
  1. By Value
  2. AAV
    1. AAV By Value
  3. Lentiviral vectors
    1. Lentiviral vectors By Value
  4. Others
    1. Others By Value
3. Non-Viral
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Cancer
  1. By Value
3. Cystic fibrosis
  1. By Value
4. Heart diseases
  1. By Value
5. Diabetes
  1. By Value
6. Hemophiles
  1. By Value
7. AIDS
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Inhalation
  1. By Value
China
1. By Vector
  1. Introduction
    1. Vector By Value
  2. Viral
    1. By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-Viral
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Cancer
    1. By Value
  3. Cystic fibrosis
    1. By Value
  4. Heart diseases
    1. By Value
  5. Diabetes
    1. By Value
  6. Hemophiles
    1. By Value
  7. AIDS
    1. By Value
  8. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Inhalation
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Vector
1. Introduction
  1. Vector By Value
2. Viral
  1. By Value
  2. AAV
    1. AAV By Value
  3. Lentiviral vectors
    1. Lentiviral vectors By Value
  4. Others
    1. Others By Value
3. Non-Viral
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Cancer
  1. By Value
3. Cystic fibrosis
  1. By Value
4. Heart diseases
  1. By Value
5. Diabetes
  1. By Value
6. Hemophiles
  1. By Value
7. AIDS
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Inhalation
  1. By Value
UAE
1. By Vector
  1. Introduction
    1. Vector By Value
  2. Viral
    1. By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-Viral
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Cancer
    1. By Value
  3. Cystic fibrosis
    1. By Value
  4. Heart diseases
    1. By Value
  5. Diabetes
    1. By Value
  6. Hemophiles
    1. By Value
  7. AIDS
    1. By Value
  8. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Inhalation
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
The rest of MEA

LATAM Market Analysis

Introduction
By Vector
1. Introduction
  1. Vector By Value
2. Viral
  1. By Value
  2. AAV
    1. AAV By Value
  3. Lentiviral vectors
    1. Lentiviral vectors By Value
  4. Others
    1. Others By Value
3. Non-Viral
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Cancer
  1. By Value
3. Cystic fibrosis
  1. By Value
4. Heart diseases
  1. By Value
5. Diabetes
  1. By Value
6. Hemophiles
  1. By Value
7. AIDS
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Inhalation
  1. By Value
Brazil
1. By Vector
  1. Introduction
    1. Vector By Value
  2. Viral
    1. By Value
    2. AAV
      1. AAV By Value
    3. Lentiviral vectors
      1. Lentiviral vectors By Value
    4. Others
      1. Others By Value
  3. Non-Viral
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Cancer
    1. By Value
  3. Cystic fibrosis
    1. By Value
  4. Heart diseases
    1. By Value
  5. Diabetes
    1. By Value
  6. Hemophiles
    1. By Value
  7. AIDS
    1. By Value
  8. Others
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Inhalation
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Gene Therapy Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Beacon Therapeutics
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Astellas Pharma Inc.
Novartis AG
Beam Therapeutics
bluebird bio, Inc.
Adverum Biotechnologies, Inc.
Benitec Biopharma
Oxford Biomedica PLC
Sangamo Therapeutics
uniQure N.V.
Verve Therapeutics, Inc.
CRISPR Therapeutics.
Krystal Biotech, Inc.
Editas Medicine
Taysha GTx
Voyager Therapeutics, Inc.
Sarepta Therapeutics, Inc.
BioMarin Pharmaceutical Inc.
MeiraGTx Limited.
Neurogene Inc.
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment